Clinical characteristics of carriers of pathogenic LDLR and АРОВ mutations

Aim. To analyze the clinical characteristics of carriers of pathogenic LDLR and АРОВ mutations, as well as the prognostic value of Dutch Lipid Clinic Network Score (DLCNS) as applied to carriage of АРОВ or LDLR.

Material and methods. The study included 1233 outpatient lipid clinic patients. Biomaterial samples from 421 patients with the hereditary dyslipidemia were studied using Next Generation Sequencing (NGS) to identify carriage of familial hypercholesterolemia (FH)-associated genes (LDLR, АРОВ, PCSK9, LDLRAP1), as well as polymorphism of the APOE gene. Statistical processing was performed using descriptive statistics methods.

Results. According to the data obtained, the most significant predictors of pathogenic LDLR mutations are the levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), family history of coronary artery disease (CAD), and previous coronary artery bypass grafting. The level of LDL-C, family history of cerebrovascular accident or CAD, and arcus senilis were more significant for verifying the carriage of pathogenic АРОВ mutations. Using screening potential carriers of FH using the DLCN or Simon-Broome diagnostic criteria, the probability of FH may be underestimated due to the discrepancy between the scale criteria and the prognostic contribution of clinical or anamnestic data. These scales do not take into account the estrogen status of potential female carriers of FH.

Conclusion. Thus, diagnostic criteria for identifying potential FH vary among different patient groups. Their diagnostic significance depends on sex, and in women, on reproductive status. Only part of DLCN and Simon-Broome criteria can be applied to assess the FH likelihood, and to a greater extent for carriage of LDLR, but not АРОВ.

1. Ezhov MV, Sergienko IV, Rozhkova TА, et al. Diagnosis and treatment of family hypercholesterinemia (russian guidelines). The Bulletin of Contemporary Clinical Medicine. 2017;10(2):72-9. (In Russ.) doi:10.20969/VSKM.2017.10(2).72-79.

2. Ezhov MV, Barbarash OL, Voevoda MI, et al. Organization of lipid centers operation in the Russian Federation — new opportunities. Russian Journal of Cardiology. 2021;26(6):4489. (In Russ.) doi:10.15829/1560-4071-2021-4489.

3. Аkioyamen LE, Genest J, Shan SD, et al. Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. BMJ Open. 2017;7(9):e016461. doi:10.1136/bmjopen-2017-016461.

4. Karpov YuA, Kukharchuk VV, Boytsov SA. Consensus Statement of the Russian National Atherosclerosis Society (RNAS) Familial hypercholesterolemia in Russia: outstanding issues in diagnosis and management. The Journal of Atherosclerosis and Dyslipidemias. 2015;(2):5-16. (In Russ.)

5. Khera AV, Hegele RA. What is familial hypercholesterolemia, and why does it matter? Circulation. 2020;141(22):1760-3.

6. Ezhov MV, Bazhan SS, Ershova AI, et al. Clinical guidelines for familial hypercholesterolemia. Ateroscleroz. 2019;15(1):58-98. (In Russ.)

7. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart Journal. 2020;41(1):111-88. doi:10.1093/eurheartj/ehz455.

8. Kim ZF, Galyavich AS, Sadykova DI, et al. Clinical and laboratory characteristics of female patients of outpatient lipidologist. The Bulletin of Contemporary Clinical medicine. 2023;16(4):27-36. (In Russ.) doi:10.20969/VSKM.2023.16(4).27-36.

9. Gerdts E, Regitz-Zagrosek V.Sex differences in cardiometabolic disorders. Nat. Med. 2019;25(11):1657-66.

10. Von Hafe P.Gender differences in lipid profile and therapy. Rev. Port. Cardiol. 2019;38(8): 571-2.

11. Pellegrini M, Pallottini V, Marin R, et al. Role of the sex hormone estrogen in the prevention of lipid disorder. Curr. Med. Chem. 2014;21(24):2734-42.